Euglycemic DKA (euDKA) as a presentation of COVID ‐19

COVID ‐19 in the setting of SGLT2 inhibitor use may precipitate euglycemic DKA separate from known acute viral illness and dehydration precipitants. There should be consideration of proactive discontinuation of these medications in these patients. AbstractCOVID ‐19 in the setting of SGLT2 inhibitor use may precipitate euglycemic DKA separate from known acute viral illness and dehydration precipitants. There should be consideration of proactive discontinuation of these medications in these patients.

Source: Clinical Case Reports - November 20, 2020 Category: General Medicine Authors: Bhagwan Dass, Andrew Beck, Cody Holmes, Glenville Morton Tags: CASE REPORT Source Type: research